Printer Friendly

COLUMBIA LABORATORIES SIGNS LETTER OF INTENT FOR TWO PATENTED WOMEN'S HEALTH CARE DIAGNOSTIC TESTS

 COLUMBIA LABORATORIES SIGNS LETTER OF INTENT FOR
 TWO PATENTED WOMEN'S HEALTH CARE DIAGNOSTIC TESTS
 HOLLYWOOD, Fla., March 31 /PRNewswire/ -- Columbia Laboratories, Inc. (AMEX: COB) announced today that it has signed a letter of intent for the exclusive worldwide marketing rights to two patented diagnostic tests; one for the detection of vaginal yeast infections and the other for the detection of bacterial vaginosis. Both of these tests were developed by Diagnostic Markers, Inc. of Englewood, Colo.
 "The licensing of these products expands the women's health care product line already being developed by Columbia. Market potential for these tests could approximate several hundred million dollars worldwide, as demonstrated by the recent success of relatively expensive over-the-counter drugs which treat yeast infections. The success of these products give evidence to the significant size of the vaginal infection market and the desire by women to expand their self help armamentarium. We expect to use our previously signed strategic alliances with large pharmaceutical companies to quickly obtain mass marketing power and access to worldwide markets," said Norman M. Meier, president and CEO.
 "Each of these tests will allow women to detect the presence of vaginal infections within 10 minutes. Diagnostic Markers, Inc. submitted an application for marketing approval to the Food & Drug Administration ("FDA") earlier this month for the Yeastest(TM). We anticipate the FDA will act on the filing in the next few months. A similar submission for the Bacterial Vaginosis Test(TM) is expected to take place early in 1993," said Dr. David Bar-Or, president of Diagnostic Markers, Inc.
 Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company established in 1987, whose objective is to develop and market on a worldwide basis, either directly or through corporate partners, a portfolio of prescription and over-the-counter drugs and cosmetics, which utilize the company's patented substance delivery technology.
 -0- 3/31/92
 /CONTACT: Margaret Roell, chief financial officer, 305-985-6545, or Helen Witters, vice president, 305-985-6524, both of Columbia Laboratories/
 (COB) CO: Columbia Laboratories, Inc.; Diagnostic Markers, Inc. ST: Florida, Colorado IN: MTC SU:


JB-AW -- FL016 -- 3620 03/31/92 17:17 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1992
Words:348
Previous Article:TJ INTERNATIONAL COMPLETES WINDOW ACQUISITION
Next Article:LINCOLN N.C. REALTY FUND ANNOUNCES DIVIDEND
Topics:


Related Articles
BAXTER DIAGNOSTICS INC., ENTERS INTO STRATEGIC CARDIAC DIAGNOSTIC ALLIANCE WITH SPECTRAL DIAGNOSTICS INC. AND PLANS FOR EQUITY INVESTMENT
HOFFMANN-LA ROCHE AND ABBOTT AGREE TO LICENSE KEY PATENTS FOR DIAGNOSTIC APPLICATIONS OF GENE AMPLIFICATION TECHNOLOGIES
RESPONSE BIOMEDICAL CORP. ANNOUNCES PLANS TO OPEN PRODUCT DEVELOPMENT LABORATORY
BioStar to Develop Influenza Diagnostic with Australian Partner
Dade International and Premier Sign National Hemostasis Contract
Abbott Laboratories and Adeza Biomedical Announce Agreement To Market Test for Preterm Labor.
Patent Litigation Settled Between Chronimed and Bayer.
Saliva Diagnostic Systems Announces New CEO; Steve Peltzman to Lead Next Phase of Company's Growth.
Corgenix Medical Corporation to Merge With Genesis Bioventures.
Saliva Diagnostic Systems Announces New COO.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters